852 Winter Street
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com .
Richard F. Pops- Chairman and Chief Executive Officer
Shane Cooke- President
Kathryn L. Biberstein- Executive Vice President, Chief Compliance Officer and Chief Administrative Officer, and Secretary Alkermes plc
Iain Brown- Senior Vice President, Finance and Chief Accounting Officer
Madeline D. Coffin- Senior Vice President, Human Resources
Elliot W. Ehrich, M.D.- Executive Vice President, Research and Development
James M. Frates- Senior Vice President, Chief Financial Officer
David J Gaffin- Senior Vice President, Chief Legal Officer
Georgianna Harris, Ph.D.- Senior Vice President, Regulatory Affairs
Craig Hopkinson, M.D.- Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs
Blair C. Jackson- Senior Vice President, Business Development
Michael J. Landine- Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.- Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman- Vice President, Government Affairs and Policy
Declan O’Connor- Senior Vice President, Operations
Phil Shanahan, Ph.D.- Vice President, Quality Operations
Mark P. Stejbach- Senior Vice President, Chief Commercial Officer
Alkermes Corporate Headquarters
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Co Westmeath, Ireland
+353 90 649 5000
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
638 articles with Alkermes
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Alkermes plc announced plans to present a poster related to nemvaleukin alfa, the company's novel, investigational, engineered interleukin-2 variant immunotherapy, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place Jan. 20-22, 2022.
Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx Conference on Thursday, Dec. 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of Directors.
Alkermes plc announced that management will participate in a fireside chat at the Stifel Virtual Healthcare Conference on Tuesday, Nov. 16, 2021 at 9:20 a.m. ET.
Alkermes plc announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology.
Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place Nov. 10-14, 2021
Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences
Alkermes plc (Nasdaq: ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific conferences this fall.
Alkermes plc Reports Third Quarter 2021 Financial Results
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered (IV) nemvaleukin alfa (nemvaleukin), in combination with pembrolizumab, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer.
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Alkermes plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin) for the treatment of platinum-resistant ovarian cancer.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Oct. 27, 2021 to discuss the company's third quarter 2021 financial results.
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
Alkermes plc (Nasdaq: ALKS) today announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U.S.) for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 29, 2021 at 8:40 a.m. ET
Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress
Alkermes plc (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 16-21, 2021.
Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Sept. 13, 2021.
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes plc announced that the U.S. Food and Drug Administration has granted Fast Track designation to nemvaleukin alfa, the company's novel, investigational engineered interleukin-2 variant immunotherapy, for the treatment of mucosal melanoma.
Alkermes plc reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021.
Alkermes plc announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program.